Literature DB >> 18180777

Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition.

Olivier ter Brake1, Karen 't Hooft, Ying Poi Liu, Mireille Centlivre, Karin Jasmijn von Eije, Ben Berkhout.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) replication in T cells can be inhibited by RNA interference (RNAi) through short hairpin RNA (shRNA) expression from a lentiviral vector. However, for the development of a durable RNAi-based gene therapy against HIV-1, multiple shRNAs need to be expressed simultaneously in order to avoid viral escape. In this study, we tested a multiple shRNA expression strategy for different shRNAs using repeated promoters in a lentiviral vector. Although highly effective in co-transfection experiments, a markedly reduced activity of each expressed shRNA was observed in transduced cells. We found that this reduced activity was due to recombination of the expression cassette repeat sequences during the transduction of the lentiviral vector, which resulted in deletions of one or multiple cassettes. To avoid recombination, we tested different promoters for multiple shRNA expression. We compared the activity of the human polymerase III promoters U6, H1, and 7SK and the polymerase II U1 promoter. Activities of these promoters were similar, irrespective of which shRNA was expressed. We showed that these four expression cassettes can be combined in a single lentiviral vector without causing recombination. Moreover, whereas HIV-1 could escape from a single shRNA, we now show that HIV-1 escape can be prevented when four shRNAs are simultaneously expressed in a cell.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180777     DOI: 10.1038/sj.mt.6300382

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  86 in total

1.  Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.

Authors:  Nick C T Schopman; Anja Braun; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

Review 3.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

4.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

Review 5.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

6.  Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

Authors:  Mario Amendola; Laura Passerini; Ferdinando Pucci; Bernhard Gentner; Rosa Bacchetta; Luigi Naldini
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

7.  The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

8.  Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications.

Authors:  Kshitij Gupta; Kirill A Afonin; Mathias Viard; Virginia Herrero; Wojciech Kasprzak; Ioannis Kagiampakis; Taejin Kim; Alexey Y Koyfman; Anu Puri; Marissa Stepler; Alison Sappe; Vineet N KewalRamani; Sarina Grinberg; Charles Linder; Eliahu Heldman; Robert Blumenthal; Bruce A Shapiro
Journal:  J Control Release       Date:  2015-07-04       Impact factor: 9.776

9.  A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Authors:  Saki Shimizu; Patrick Hong; Balamurugan Arumugam; Lauren Pokomo; Joshua Boyer; Naoya Koizumi; Panyamol Kittipongdaja; Angela Chen; Greg Bristol; Zoran Galic; Jerome A Zack; Otto Yang; Irvin S Y Chen; Benhur Lee; Dong Sung An
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.